Publications by authors named "C De La Calle"
Article Synopsis
- The Prime-2-CoV_Beta is a new COVID-19 vaccine designed to target the SARS-CoV-2 spike and nucleocapsid antigens, and was tested in a phase I clinical trial involving 60 healthy adults in Germany from June 2022 to June 2023.
- The trial showed that the vaccine had a good safety profile with only mild to moderate side effects, such as pain at the injection site, fatigue, and headache, and no serious adverse events were reported.
- Immunization resulted in strong immune responses, particularly at higher doses, leading to significant increases in antibodies against SARS-CoV-2 and its variants, indicating the vaccine's potential for broader protection
Introduction: Advanced malignant melanoma is a very aggressive disease, historically with poor prognosis before the new advances with immunotherapy and targeted therapies that have changed the standard of care, especially in cutaneous melanoma. Peru has aggressive features such as higher rates of acral lentiginous melanoma (ALM) subtype with historically shorter survival.
Methods: This study describes Peruvian patients with advanced melanoma treated with immunotherapy (nivolumab) in two oncological institutions (public and private), including the discussion of the impact on overall survival (OS) divided by subtype (with incidence in ALM histology) and potential biomarkers that could be related to prognosis.
Article Synopsis
- The study examines whether diet quality and inflammatory potential affect the risk of prostate cancer grade reclassification in men under active surveillance, revealing that diet's influence remains uncertain.
- A cohort of 886 men diagnosed with low-grade prostate cancer completed dietary assessments to evaluate their adherence to dietary guidelines and inflammatory potential.
- Results showed that after about 6.5 years, about 21% of participants experienced grade reclassification, indicating an ongoing need for research on dietary impacts on prostate cancer outcomes.